Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Stock Information for Sangamo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sangamo Therapeutics Inc.

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.